A Case Report of Pregnancy During Use of Targeted Therapeutics for Cystic Fibrosis

J Obstet Gynecol Neonatal Nurs. 2017 Jan-Feb;46(1):72-77. doi: 10.1016/j.jogn.2016.08.011. Epub 2016 Nov 19.

Abstract

New therapeutics, such as ivacaftor, and the combination drug lumacaftor/ivacaftor that target the underlying genetic cause of cystic fibrosis are being hailed as game-changers in this era of personalized medicine. Although these drugs improve lung function, their effects on female fertility have not been studied. In this case report we describe one woman's experience with ivacaftor and her unanticipated pregnancy. Implications related to comprehensive sexual and reproductive health care for women with cystic fibrosis are presented.

Keywords: cystic fibrosis; fertility; ivacaftor; lumacaftor/ivacaftor; sexual and reproductive health.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aminophenols / administration & dosage*
  • Aminopyridines / administration & dosage*
  • Benzodioxoles / administration & dosage*
  • Cystic Fibrosis / drug therapy*
  • Dose-Response Relationship, Drug
  • Drug Combinations
  • Female
  • Humans
  • Precision Medicine
  • Pregnancy
  • Pregnancy Complications / drug therapy*
  • Quinolones / administration & dosage*

Substances

  • Aminophenols
  • Aminopyridines
  • Benzodioxoles
  • Drug Combinations
  • Quinolones
  • lumacaftor, ivacaftor drug combination